For over 25 years, Astellas Pharma has been engaged with the transplantation community. We have made significant advances in immunosuppression, improving outcomes for kidney, liver and heart transplant recipients.

Immunosuppressants are a class of drugs that suppress the immune response through various mechanisms. In organ transplantation, immunosuppressants are used to prevent the body from either recognising or attacking the foreign organ via various immune responses.

With the goal of improving the quality of patients’ lives, Astellas has worked in partnership with the transplant community, providing historical support to a number of causes, such as the World Transplant Games (WTG) and TACKERS (Transplant Adventure Camp for Kids).

Astellas is committed to continually striving to improve immunosuppression, and ultimately the lives of patients, by investing in the future of transplantation. The goal of our on-going research is to find compounds that will anticipate and address current and future unmet needs in the field of transplantation. We are dedicated to finding new ways to improve patient and graft survival through continued investment in our pipeline of potential future therapies, which includes investigation of all major signalling pathways.

Our mission is to play a key role in the advancement of transplantation and begins with addressing today’s unmet needs, with a positive look to the future. Astellas Pharma is committed to endeavoring to provide medicines that are recognised worldwide as improving outcomes for patients, in every way possible, following kidney, liver and heart transplantation.

MAT-IE-NON-2024-00019  - Date of Preparation April 2024.